Tianyu Liu, MD
Retina Specialist · Royal Oak, MINPI 1780243246
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,462 of the $5,122 with a category attached, or 67.6%. 16 manufacturers reported payments, led by Eyepoint US, Inc. at 29.0% of the total. Reporting peaked in 2024 at $3,660 and has fallen 84.1% since, to $584 in 2025.
Across 55 payments — averaging $93.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$1K
- Alimera Sciences, Inc.$1K
- Genentech USA, Inc.$569
- Apellis Pharmaceuticals, Inc.$314
- Regeneron Healthcare Solutions, Inc.$310
- Astellas Pharma US Inc$225
- plus $1K from 10 others
What the payments were for
- Consulting fees$1,10021%
- Speaking & faculty fees$4609%
- Food & beverage$3,46268%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 4 | $1,483 |
| Alimera Sciences, Inc. | 8 | $1,191 |
| Genentech USA, Inc. | 7 | $569 |
| Apellis Pharmaceuticals, Inc. | 7 | $314 |
| Regeneron Healthcare Solutions, Inc. | 6 | $310 |
| Astellas Pharma US Inc | 4 | $225 |
| AbbVie | 2 | $224 |
| Bausch & Lomb Americas Inc. | 3 | $202 |
| Coherus Oncology, Inc. | 2 | $156 |
| Regeneron | 1 | $125 |
| Sandoz | 3 | $84 |
| Genentech, Inc. | 1 | $73 |
| Alcon | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $64 |
| Biogen | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,122 in reported general payments places this provider in the 60th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 213 | $10,066 |
| Ketorolac Tromethamine | 86 | $2,802 |
| Brimonidine Tartrate | 34 | $1,567 |
| Gentamicin Sulfate | 95 | $906 |
| Dorzolamide Hcl | 19 | $612 |
| Ofloxacin | 48 | $533 |
| Latanoprost | 33 | $518 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $339 |
| Timolol Maleate | 22 | $278 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Sandeep RandhawaRoyal Oak$94K
- Kimberly DrenserRoyal Oak$79K
- Adam WeinerRoyal Oak$31K
- Michael TreseRoyal Oak$26K
- Antonio CaponeRoyal Oak$20K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.